BioPhy

Philadelphia, Pennsylvania, United States

Leveraging the possibilities of modern science and advanced technologies, BioPhy is committed to transforming the way promising drugs are identified and developed. With the help of its patent-pending predictive AI engine, BioPhy works to enhance the outcomes of clinical trials, reduce failure rates, and accelerate the pace of developing new drugs to improve the quality of healthcare outcomes across the globe. By integrating advanced probabilistic models, proprietary data, and geometric deep learning across the industry’s most advanced knowledge graph, we deliver unmatched predictive power and generative capabilities improving decision-making, productivity, and economics across the drug development lifecycle. Our technology updates it’s understanding of over 35,000 ongoing clinical trials every day and has been validated to predict trial outcomes in over 2,200+ studies over the past 3 years with over 80% accuracy, outperforming both human experts and other AI solutions.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out BioPhy on @MedStartr Today #MedMo #MedStartrVentures

https://www.medstartr.ai/s/YS2kojGiFiw

Get Involved in BioPhy

Company Info

Founded: 2019
Website: www.biophy.ai/

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of BioPhy?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.